Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31826340

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2019 Dec 12
First author
Hughes TP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2020 Mar;17(3):135. doi: 10.1038/s41571-019-0324-z.
    note
    Source null
    related pmid
    31900441
    relationship
    Comment in
  2. citation
    N Engl J Med. 2020 Apr 2;382(14):1378-1379. doi: 10.1056/NEJMc2000116.
    note
    Source null
    related pmid
    32242375
    relationship
    Comment in

Authors and identifiers

  1. name
    Hughes TP
    type
    Author
  2. name
    Mauro MJ
    type
    Author
  3. name
    Cortes JE
    type
    Author
  4. name
    Minami H
    type
    Author
  5. name
    Rea D
    type
    Author
  6. name
    DeAngelo DJ
    type
    Author
  7. name
    Breccia M
    type
    Author
  8. name
    Goh YT
    type
    Author
  9. name
    Talpaz M
    type
    Author
  10. name
    Hochhaus A
    type
    Author
  11. name
    le Coutre P
    type
    Author
  12. name
    Ottmann O
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Hughes TP
    type
    Author
  2. name
    Mauro MJ
    type
    Author
  3. name
    Cortes JE
    type
    Author
  4. name
    Minami H
    type
    Author
  5. name
    Rea D
    type
    Author
  6. name
    DeAngelo DJ
    type
    Author
  7. name
    Breccia M
    type
    Author
  8. name
    Goh YT
    type
    Author
  9. name
    Talpaz M
    type
    Author
  10. name
    Hochhaus A
    type
    Author
  11. name
    le Coutre P
    type
    Author
  12. name
    Ottmann O
    type
    Author
bibliography ids
  1. nci-bib-8c24a69e47437f3bcec1836b
book metadata
content sha256
42e15b07156e8b8f9eaf58c2191721627c78d1bf1745dfb9e5da70e8dc297519
document type
citation
dois
  1. 10.1056/NEJMoa1902328
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:31826340
immutable id
pubmed:31826340@42e15b07156e8b8f9eaf58c2191721627c78d1bf1745dfb9e5da70e8dc297519
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
24
name
The New England journal of medicine
nlm unique id
0255562
pages
2315-2326
volume
381
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2020 Mar;17(3):135. doi: 10.1038/s41571-019-0324-z.
    note
    Source null
    related pmid
    31900441
    relationship
    Comment in
  2. citation
    N Engl J Med. 2020 Apr 2;382(14):1378-1379. doi: 10.1056/NEJMc2000116.
    note
    Source null
    related pmid
    32242375
    relationship
    Comment in
outcomes validated
false
pmid
31826340
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
32f47b47096c6d822c7d03b4af70cfa1f1d3215fa4b366d52f828c5829c1dffa
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2019 Dec 12
precision
day
year
2019
publication types
  1. Clinical Trial, Phase I
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31826340/
title
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

Preserved source evidence · Not medical advice